Citius Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022
Net Income	-23.64	-24.76	-21.15	-12.7	-10.87
Stock-Based Compensation	10.47	8.32	7.5	1.97	-
Other Operating Activities	1.06	1.06	0.58	0.58	1.15
Change in Inventory	-6.89	-12.65	-2.13	-	-
Change in Accounts Payable	4.57	9.52	2.42	1.2	0.18
Change in Other Net Operating Assets	5.06	13.02	12.91	8.96	9.53
Operating Cash Flow	-12.85	-5.49	0.13	-	-
Sale (Purchase) of Intangibles	-10.15	-5.75	-5	-	-
Investing Cash Flow	-10.15	-5.75	-5	-	-
Long-Term Debt Issued	-	-	3.8	-	-
Net Debt Issued (Repaid)	-	-	3.8	-	-
Issuance of Common Stock	30.29	15.17	-	-	-
Other Financing Activities	-	-	1.07	-	-
Financing Cash Flow	30.29	15.17	4.87	-	-
Net Cash Flow	7.3	3.92	0	-	-
Cash Interest Paid	0.2	0.19	-	-	-
Levered Free Cash Flow	-24.72	-8.13	-1.94	4.55	-
Unlevered Free Cash Flow	-24.56	-7.99	-1.94	4.55	-
Change in Working Capital	-1.31	9.89	13.2	10.16	9.71

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q